According to filings with the U.S. Securities and Exchange Commission, Kano Therapeutics is raising up to $5,050,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Floris Engelhardt played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Kano Therapeutics
Kano Therapeutics is a founder-led biotech startup enabling safe, effective, and flexible correction of gene-length stretches of DNA through a new class of biomaterials. By building a one stop shop product development platform for single-stranded DNA templates that combines manufacturing, application, and computational tools we bridge the gap between editing genes and totally replacing them, empowering scientists, labs, and companies with the building blocks they need to cross the chasm to cures.

To learn more about Kano Therapeutics, visit http://www.kanotherapeutics.com/

Contact:
Floris Engelhardt, Chief Executive Officer
617-485-9448
https://www.linkedin.com/in/floris-engelhardt/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.